Opexa Therapeutics (OPXA) Tops Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. DAL
9. TMUS
10. VZ

Go back to Opexa Therapeutics (OPXA) Tops Q1 EPS by 4c

Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update

May 12, 2016 4:01 PM EDT

THE WOODLANDS, TX -- (Marketwired) -- 05/12/16 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including Tcelna for multiple sclerosis (MS) and OPX-212 for neuromyelitis optica (NMO), today reported financial results for the quarter ended March 31, 2016, and provided an update on the Company's recent corporate developments.

"We are pleased to be coming off a productive quarter and progressing further towards the completion of our Phase 2b Abili-T trial in secondary progressive MS," stated Neil K. Warma, President and Chief Executive Officer of Opexa.... More